![](/img/cover-not-exists.png)
150O Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
Hong, D.S., Dowlati, A., Burris, H.A., Lee, J.J., Brose, M.S., Farago, A.F., Bauer, T.M., Taylor, M., Shaw, A.T., Smith, S., Nanda, N., Cruickshank, S., Cox, M.C., Doebele, R.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw579.002
Date:
December, 2016
File:
PDF, 43 KB
english, 2016